ReleaseWire

Organ Transplantation Market Will Generate New Growth Opportunities by 2023

Organ Transplantation Market information by types (kidney, liver) products, commercialized products (Zenapax, Prograf, Cellcept, Myfortic, Neoral), End User - Forecast to 2027

Posted: Monday, March 12, 2018 at 9:51 AM CDT

Pune, India -- (SBWire) -- 03/12/2018 --Organ transplantation is the replacement of the diseased or damaged organ with a health organ. Organs such as a kidney may be donated by living donors or harvested from brain-dead organ donors. Organ dysfunction caused due to severe injuries, cancer, organ failure and/or genetic disorders necessitate the requirement for organ transplant procedures. Advances in technology and development in the medical sector has made transplantation possible.

The Global Organ Transplantation Market is expected to grow at a CAGR of 9.8% during forecasted period 2017-2023.

Kidney, heart, lungs, liver and many more can be transplanted. An increasing number of organ transplantation surgeries across the globe are the major driving factor for the growth of the market. Technological development, increasing prevalence of chronic diseases, rising aging population and changing lifestyle has also contributed to the growth of the market. However, high cost of treatment and increasing incident of organ failure has hampered the growth of the market.

Key players for global organ transplantation market

Novartis International AG (Switzerland), Terumo Medical Corporation (US), Transonic (US), F. Hoffmann-La Roche Ltd. (Switzerland), Astellas Pharma, Inc (Japan), Preservation Solutions, Inc. (US), OrganOX Limited (UK), Bio Med Pvt. Ltd. (US), Transplant Biomedical (UK), TransMedic, Inc. (US), Accord Healthcare GmbH (Spain), Sanofi (France), Pfizer, Inc. (US), Veloxis Pharmaceuticals A/S (Denmark), GlaxoSmithKline Plc. (UK)

Novartis International AG is a Swiss multinational company headquartered in Switzerland and is one of the largest pharmaceutical companies. They are the leading manufacturer of analgesic drugs. In 2016, company has acquired Selexys Pharmaceuticals to increase its market. Company has launched, Zortress is the first in over a decade approved by FDA to prevent organ rejection in adult liver transplant patients.

Get a Brochure of This Report @ https://www.marketresearchfuture.com/sample_request/915 .

Segmentation:

Global organ transplantation market is segmented on the basis of type of organ, into heart, kidney, liver, lungs, and other. On the basis of products, they are segmented into organ preservation solutions, transplant diagnostics, tissue products and other. On the basis of type of transplant the market is segmented into autograft, allograft and allotransplantation, xenograft and xenotransplantation and other.

On the basis of treatment the market is segmented into analgesic, immunosuppressant and other. Immunosuppressant is further segmented into calcineurin inhibitors, mTOR inhibitor, antiproliferative agents, steroids and other. Calcineurin Inhibitors are sub segmented into tacrolimus and cyclosporine. mTOR inhibitor is sub segmented into sirolimus and everolimus.

On the basis of end users the market is sub segmented into hospitals, transplant centers and other.

Brief TOC

1 Introduction

1.1 Definition

1.2 Scope of Study

1.2.1 Research Objective

1.2.2 Assumptions & Limitations

1.2.2.1 Assumptions

1.2.2.2 Limitations

1.3 Market Structure

2 Research Methodology

2.1 Research Process

2.2 Primary Research

2.3 Secondary Research

Grab Attractive Discount @ https://www.marketresearchfuture.com/check-discount/915 .

3 Market Dynamics

3.1 Drivers

3.2 Restraints

3.3 Opportunities

3.4 Macroeconomic Indicators

4 Market Factor Analysis

…TOC Continued


Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.